Biologic therapy is increasingly used to treat autoimmune disorders in developed markets, but usage is still low in emerging markets. This analysis was conducted to identify factors associated with current use of biologic medication among patients with autoimmune disorders in emerging markets.
 Biologic therapies have been acknowledged as effective treatments for a variety of autoimmune diseases.
However, the associated costs are high due to the difficulty of manufacture. A study by the National Institute for Health and Care Excellence (NICE) found in UK, biologic drugs cost twenty times as much as conventional therapy 1 .  The United States and Europe are currently the bulk of the biologics market, but growth is projected to slow in the next few years 2 . By 2015, BRIC (Brazil, Russia, India, and China) markets are expected to account for over 25% of global biologic revenues 3 .  Due to the cost of biologic treatments, government reimbursement is a primary driver in consumer use.
China's market already exceeds $1 billion in sales, driven largely by reimbursement programs. Brazil and Russia, where biologics are not typically reimbursed, are expected to be near-term opportunities due to their high median income 2 .
BACKGROUND

Data Source
 Data were taken from the 2011 and 2012 National Health and Wellness Survey (NHWS), a self-reported survey recruited through a combination of panel and field recruitment in Brazil (2011 and 2012), urban China (2012), and urban Russia (2011). These countries were aggregated and are referred to as emerging markets in this analysis.
Measures
 Disease status: Physician diagnosis for a variety of medical conditions was collected through self-report.
-Ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis were of particular interest and are collectively referred to as autoimmune conditions in this analysis. -Self-reported physician diagnoses were also used to calculate the Charlson Comorbidity Index (CCI).  Medication use: Prescription medication (Rx) use for autoimmune conditions was also assessed through self-report.
-Respondents who reported intravenous infusions or injections of abatacept, adalimumab, efalizumab, etanercept, infliximab, rituximab, tocilizumab, or ustekinumab for any autoimmune condition were considered to be biologic users for this analysis.  Fear of needles was assessed through agreement with the statement, "I am afraid of needles" on a 5-point scale (Strongly disagree, Disagree, Neither agree nor disagree, Agree, Strongly agree). Those who responded with Agree or Strongly agree were classified as having a fear of needles.  Demographic (e.g., household income, out-of-pocket costs) and general health characteristics (e.g., height, weight) were also collected through self-report.
Analysis
 Binary logistic regression was used to test which patient characteristics were associated with use of a biologic medication by collapsing across emerging markets while accounting for covariates.
METHODS
 Of the 54,033 respondents in Brazil, Russia, and China, N=2,756 (5.1%) had been diagnosed with at least one autoimmune condition; see Table 1 .
-59% of emerging market autoimmune patients use any type of Rx.
-20% of emerging market autoimmune patients use a biologic.
-The distribution of biologic use very different across countries:  29% of Chinese autoimmune patients  12% of Russian autoimmune patients  6% of Brazilian autoimmune patients  Rheumatoid arthritis was the condition most often treated by biologics (30%).
RESULTS
 All data are self-reported and may be subject to recall error.  Due to the cross-sectional nature of the analysis, the relationships noted in this analysis are not necessarily causal in nature.
LIMITATIONS
Regression Analysis
 Multivariable analysis comparing biologic users to non-biologic Rx users revealed that the biggest factor associated with biologic use was country; see Figure. -Odds of biologic use in other countries relative to China were lower by:  71% (OR: 0.289; 95% CI: 0.181, 0.461) in Brazil  79% (OR: 0.213; 95% CI: 0.126, 0.360) in Russia  There were few other significant associations.
-CCIs of biologic users were significantly higher (OR: 1.179; 95% CI: 1.101, 1.264).
-Biologic use also was associated with a 57% increase in fear of needles (95% CI: 1.177, 2.093) and 137% increase in high out-of-pocket costs (95% CI: 1.040, 5.422).  When the model was run only on China data, treating physician was the only additional significant covariate; treatment by a specialist decreased odds of biologic use (data not shown), but individual factors such as income, severity, or length of diagnosis still were not significant.
 Country emerged as the most influential predictor of biologic use, with use much more common in China than in the other emerging markets. This is likely because China's healthcare infrastructure supports biologic medications, while Brazil and Russia lag behind in reimbursing these treatments.  Since patients receiving biologic treatment were more afraid of needles than their counterparts, the injectable nature of biologic therapy does not appear to be an important barrier to their use in these markets.  Though high out-of-pocket costs were associated with biologic use, this is more likely to be an effect of the treatments than a cause.
DISCUSSION
 The primary driver of biologic use in the emerging markets appears to be economic, with reimbursement driving treatment decisions in autoimmune diseases. 
CONCLUSIONS
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